Da-Ae Yu1, Se Hee Min2, Jaeryong Song2, Jong Seo Park1, Hanjae Lee1, Jungyoon Ohn1, Kyu Han Kim1,3,4. 1. Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea. 2. Department of Medicine, Seoul National University Hospital, Seoul, Korea. 3. Laboratory of Cutaneous Aging and Hair Research, Clinical Research Institute, Seoul National University Hospital, Seoul, Korea. 4. Institute of Human Environment Interface Biology, Seoul National University College of Medicine, Seoul, Korea. kyuhkim@snu.ac.kr.
Abstract
BACKGROUND: Topical timolol is widely used for treatment of superficial infantile hemangioma (IH). However, little is known about factors that affect the response to topical timolol treatment. OBJECTIVE: This study aimed to investigate the efficacy, safety, and predictive value for good response to topical timolol for IH. METHODS: A retrospective review of medical records and clinical photos of 328 patients with IH treated with topical timolol 0.5% solution was conducted. Serial clinical photographs were compared with those at the initial visit using a 100-mm visual analogue scale (VAS). Treatment response was defined as an improvement of at least 75% from baseline in IH lesions within 12 months of treatment. RESULTS: Overall, IH patients treated with topical timolol showed significant improvement from baseline, showing that the final VAS score within 12 months of treatment was 69.7±20.4. The multivariable logistic regression analysis showed age at initiation of treatment (p=0.007), length of gestation and fetal growth (p=0.03), depth (p=0.01), and flexural area (p=0.007) were significantly associated with treatment response. Only four patients (1.1%) reported local irritation. CONCLUSION: This study demonstrated that topical timolol treatment was an effective and well-tolerated treatment for IHs. Physicians are encouraged to consider several patient- or lesional factors that might affect treatment response to achieve better clinical outcomes.
BACKGROUND: Topical timolol is widely used for treatment of superficial infantile hemangioma (IH). However, little is known about factors that affect the response to topical timolol treatment. OBJECTIVE: This study aimed to investigate the efficacy, safety, and predictive value for good response to topical timolol for IH. METHODS: A retrospective review of medical records and clinical photos of 328 patients with IH treated with topical timolol 0.5% solution was conducted. Serial clinical photographs were compared with those at the initial visit using a 100-mm visual analogue scale (VAS). Treatment response was defined as an improvement of at least 75% from baseline in IH lesions within 12 months of treatment. RESULTS: Overall, IH patients treated with topical timolol showed significant improvement from baseline, showing that the final VAS score within 12 months of treatment was 69.7±20.4. The multivariable logistic regression analysis showed age at initiation of treatment (p=0.007), length of gestation and fetal growth (p=0.03), depth (p=0.01), and flexural area (p=0.007) were significantly associated with treatment response. Only four patients (1.1%) reported local irritation. CONCLUSION: This study demonstrated that topical timolol treatment was an effective and well-tolerated treatment for IHs. Physicians are encouraged to consider several patient- or lesional factors that might affect treatment response to achieve better clinical outcomes.
Authors: B Nedelec; N J Forget; T Hurtubise; S Cimino; F de Muszka; A Legault; W L Liu; A de Oliveira; V Calva; J A Correa Journal: Skin Res Technol Date: 2015-09-01 Impact factor: 2.365
Authors: Andre Vadimovich Moyakine; Jorien Maria Kerstjens; Saskia Spillekom-van Koulil; Catharina Joanna Maria van der Vleuten Journal: J Am Acad Dermatol Date: 2016-03-24 Impact factor: 11.527
Authors: Lisa Weibel; Marjam J Barysch; Helene S Scheer; Ingo Königs; Kathrin Neuhaus; Clemens Schiestl; Katharina Rentsch; Daniel M Müller; Martin Theiler Journal: Pediatr Dermatol Date: 2016-02-03 Impact factor: 1.588
Authors: A Munden; R Butschek; W L Tom; J S Marshall; D M Poeltler; S E Krohne; A B Alió; M Ritter; D F Friedlander; V Catanzarite; A Mendoza; L Smith; M Friedlander; S F Friedlander Journal: Br J Dermatol Date: 2014-04 Impact factor: 9.302
Authors: Byung Wook Kim; Ik Jun Moon; Woo Jin Yun; Bo Young Chung; Sang Duck Kim; Ga-Young Lee; Sung Eun Chang Journal: Ann Dermatol Date: 2016-05-25 Impact factor: 1.444